Supreme Holdings & Hospitality (India) Ltd. Share Price

Premierpol q2 profit rises to ₹98 million

(PREMIERPOL) reported standalone Q2 net profit of ₹98 million, up from ₹80 million year-on-year. Revenue stood at ₹1.15 billion versus ₹834 million a year ago. EBITDA came in at ₹134 million compared with ₹113 million previously. EBITDA margin stood at 11.7 percent versus 13.6 percent a year earlier. Revenue growth outpaced the rise in profit. The key numbers are Q2 profit of ₹98 million, revenue of ₹1.15 billion and EBITDA margin of 11.7 percent. This shows topline growth for the company. Peers such as Supreme Industries, Astral and Prince Pipes may face comparison on margins. Near-term prices could react to the results. Risks include further margin pressure from higher input costs. Competitors listed: Supreme Industries, Astral, Prince Pipes. We have no financial interest in this news.

See More

Apollo Hospitals rebounds 4.8% from 61.8% retracement

Apollo Hospitals rose 4.8 percent in the week ended 9 October 2026 after a 17 percent fall, with Rs 8,180 resistance and Rs 7,600 support in focus. Apollo Hospitals Enterprise Limited [

] rose 4.8 percent on Friday 9 October 2026, after a 17 percent fall from its high in three weeks. The bounce came near the 61.8 percent retracement of the rally made from 23 January 2026 to 23 September 2026. Before the fall, the stock spent nearly three months in a Rs 8,500 to Rs 9,070 range. The breakdown from this range was sharp, and the higher high and higher low structure is now broken. A broad hospital sector sell-off on 30 September, after Supreme Court remarks on medicine mark-ups, added to the pressure. The key question is what the Friday bounce means. It may be fresh buying interest, or only short covering after a sharp fall. Price reaction near the next resistance will help to answer this. What next: Rs 8,180 is the immediate resistance. A close above it with strong volume may show real buying. Rs 7,600 is the support, and a close below it may bring back the selling. Conclusion: the view stays neutral until price reacts to the sharp decline. Disclosure & Disclaimer: I and my family members do not hold any position in the stock discussed. This content is provided solely for informational and educational purposes and should not be construed as investment advice or a recommendation to buy or sell any security. Investments in the securities market are subject to market risks. Please read all related documents carefully before investing.

See More

DELTA CORP — THE REGULATORY CLOUD COULD BECOME THE BIGGEST

Sometimes the biggest opportunity isn't hiding in growth. It's hiding in uncertainty. Delta Corp is India's only listed gaming and hospitality company, with offshore and land-based casinos, hotels and related entertainment assets. It currently holds 3 of Goa's 6 offshore gaming licences. But the business has been hit by one massive issue: GST + regulation. The 28% GST framework on casino chip purchases has materially changed the economics of the industry. And the latest quarter shows the impact. Q1 FY27 consolidated revenue fell around 9% YoY to ₹178 crore. The company reported a ₹212 crore net loss, largely because of an exceptional loss of about ₹307 crore. Excluding exceptional items, PBT remained positive at roughly ₹28 crore. So the headline loss doesn't tell the entire story. The core operating business is still generating profits. And hospitality is showing momentum. Hospitality revenue jumped nearly 38% YoY to ₹16.6 crore in Q1 FY27, while casino revenue was ₹151.9 crore. Now comes the real optionality. Delta and its subsidiaries are challenging GST demands based on the industry's dispute over whether tax should apply to gross bet value/face value rather than actual gaming revenue/rake. The company has obtained stays on relevant proceedings, and the broader industry matter has reached the Supreme Court. If the regulatory framework becomes more favourable, the earnings equation could change dramatically. Lower tax burden → Better gaming economics → Higher profitability → Stronger cash generation → Potential re-rating Then add the assets. Goa casinos. Land-based gaming. Hotels. Daman hospitality. A recognised Deltin brand. And an established position in India's organised gaming industry. That's why Delta is interesting. Not because the current quarter is strong. It isn't. GST outcome. Regulatory changes. Casino demand. High taxation. Legal uncertainty. Gaming restrictions.

See More

Hospital Stocks Face Valuation Reset Risk on Price Caps

Indian hospital stocks face a potential valuation reset as concerns over medicine price controls add to regulatory, cost and competitive pressures. Nomura said the sector’s high valuations leave limited room for margin pressure, after Supreme Court observations on steep mark-ups charged by private hospitals triggered a sharp sell-off. The Supreme Court questioned high mark-ups on medicines and medical consumables, citing a cancer drug with an MRP of ₹27,000 compared with a retailer price of ₹2,700. The court also questioned the practice of requiring patients to purchase medicines through in-house hospital pharmacies and suggested whether a uniform 16% margin could be applied to medicines. Nomura said the immediate earnings impact remains uncertain because the final regulatory framework is not yet clear. However, it highlighted the sector’s sharp re-rating, with the average valuation multiple of Indian hospitals expanding 81% between December 2019 and September 2026, compared with a 30% contraction for international peers. Indian hospital stocks now trade at around a 121% premium to global peers, making them vulnerable if profitability moderates.

See More

JSW Steel Ltd credit-rating upgrade, and bond fundraising

On 3 October 2026, the Supreme Court scrapped JSW Steel’s ₹19,700 crore resolution plan for Bhushan Power & Steel Ltd (BPSL), calling it “illegal” and ordering liquidation of the debt-ridden company. The plan had earlier been approved by BPSL’s Committee of Creditors, and JSW Steel had completed the acquisition and integration of BPSL into its operations. This is a major negative development for JSW Steel, as BPSL was a key part of its capacity expansion strategy and had been contributing to consolidated volumes and earnings. JSW Steel is planning to raise about ₹1,350 crore (around $140 million) through three- or four-year bonds in the October–December 2026 quarter, subject to favourable market conditions. This is part of a broader JSW Group fundraising plan of about $300 million, with JSW Energy also raising around ₹1,500 crore. JSW Steel’s last bond issuance was over two years ago, and the company currently has outstanding bonds of over ₹6,100 crore.

See More

Supreme Court Scrutiny on Medicine Mark-ups

Hospital stocks remain in the spotlight after the Supreme Court raised sharp concerns over steep mark-ups on medicines sold to patients at private hospitals. A bench flagged a cancer drug supplied to retailers at around ₹2,700 but carrying an MRP of ₹27,000 — nearly a tenfold difference — and questioned why the existing 16% trade margin cap on scheduled drugs has not been extended to non-scheduled medicines that dominate the market. The court also directed the Centre to examine practices compelling patients to buy from in-house or designated hospital pharmacies. The matter is listed for further hearing on October 12. The remarks triggered a sharp sell-off, with the BSE Hospitals Index falling about 5% and chains such as

Healthcare, KIMS and others declining 5-6%. Brokerages have assessed the potential earnings hit. Goldman Sachs estimates a 2-7% EBITDA impact in scenarios with no mitigation, though it notes that modest pricing adjustments or greater use of package billing could cushion the effect. Emkay remains constructive on the sector, assigning Buy ratings to KIMS (target ₹850) and Park Medi World, and Add ratings to Max Healthcare (₹1,150), Global Health/Medanta (₹1,500) and Rainbow Children’s Medicare (₹1,550).

See More